The Cancer Research UK Drug-DNA Interactions Research Group was established in 1995 with the aim of contributing to the development of new and improved cancer therapies based on DNA as a target. Research The activities of the group are centred on the following areas. The development and exploitation of methods to study drug-DNA interactions, and their repair, at the genome, gene, sub-gene and single nucleotide level in naked DNA and intact cells (both in vitro and in clinical samples). To use the information derived from experiments in biological systems to assist in the design and evaluation of novel DNA interacting drugs, in particular, DNA interstrand cross-linking agents, and DNA sequence specific agents as potential modulators of gene expression. To define the major repair pathways for drug-DNA adducts and to explore the relationship between different types of drug-induced DNA damage, the efficiency of repair of these lesions, and biological response. To determine the molecular basis of inherent sensitivity of some tumour types to DNA damaging agents and the molecular basis of clinical acquired resistance to DNA damaging drugs in order to develop strategies to overcome or circumvent this resistance.